Table 1.
Patho‐clinical profiles of the development and validation sets
| Factors | Development set (n = 1121) | Validation set (n = 864) | P |
|---|---|---|---|
| Age (years) | 61 (22–92) | 61 (19–89) | 0.844 |
| Gender | 0.507 | ||
| Male | 606 (54.1%) | 480 (55.6%) | |
| Female | 515 (45.9%) | 384 (44.4%) | |
| Pathology | 0.397 | ||
| AC | 938 (83.7%) | 735 (85.1%) | |
| Non‐AC | 183 (16.3%) | 129 (14.9%) | |
| Smoking history | 0.445 | ||
| Yes | 270 (24.1%) | 221 (25.6%) | |
| No | 851 (75.9%) | 643 (74.4%) | |
| T stage | 0.753 | ||
| T1–2 | 917 (81.8%) | 702 (81.3%) | |
| T3–4 | 204 (18.2%) | 162 (18.7%) | |
| N stage | 0.517 | ||
| N0 | 596 (53.2%) | 472 (54.6%) | |
| N+ | 525 (46.8%) | 392 (45.4%) | |
| M stage | 0.850 | ||
| M0 | 748 (66.7%) | 580 (67.1%) | |
| M1 | 373 (33.3%) | 284 (32.9%) | |
| Clinical stage | 0.376 | ||
| I | 345 (30.8%) | 282 (32.6%) | |
| II–IV | 776 (69.2%) | 582 (67.4%) | |
| EGFR | 0.699 | ||
| 19del/L858R | 601 (53.6%) | 459 (53.1%) | |
| Other mutation | 28 (2.5%) | 27 (3.1%) | |
| Wild type | 492 (43.9%) | 378 (43.8%) | |
| Lung metastasis | 0.693 | ||
| Yes | 75 (6.7%) | 54 (6.3%) | |
| No | 1046 (93.3%) | 810 (93.8%) | |
| Brain metastasis | 0.215 | ||
| Yes | 134 (12.0%) | 88 (10.2%) | |
| No | 987 (88.0%) | 776 (89.8%) | |
| Bone metastasis | 0.629 | ||
| Yes | 83 (7.4%) | 69 (8.0%) | |
| No | 1038 (92.6%) | 795 (92.0%) | |
| CEA (ng/mL) | 2.45 (0.00–8428.00) | 2.63 (0.00–6188.00) | 0.845 |
| Cyfra 21‐1 (ng/mL) | 0.00 (0.00–335.50) | 0.00 (0.00–317.90) | 0.859 |
Continuous and categorical data are presented as median with range and as number with percentage (%), respectively. AC, adenocarcinoma; CEA, carcinoembryonic antigen.